Surrozen, Inc. is a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 40 full-time employees. The company went IPO on 2020-11-23. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Follow-Up Questions
Who is the CEO of Surrozen Inc?
Mr. Craig Parker is the President of Surrozen Inc, joining the firm since 2018.
What is the price performance of SRZN stock?
The current price of SRZN is $13.06, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Surrozen Inc?
Surrozen Inc belongs to Biotechnology industry and the sector is Health Care
What is Surrozen Inc market cap?
Surrozen Inc's current market cap is $111.9M
Is Surrozen Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Surrozen Inc, including 3 strong buy, 4 buy, 1 hold, 0 sell, and 3 strong sell
